Intradural lumbar disc herniation is a rare complication of disc disease. The reason for the tearing of the dura matter by a herniated disc is not clearly known. Intradural disc herniations usually occur at the disc levels and are often seen at L4-L5 level but have also been reported at other intervertebral disc levels. However, intradural disc herniation at mid-vertebral levels is rare in the literature and mimics an intradural extramedullary spinal tumor lesion in radiological evaluation. Although magnetic resonance imaging (MRI) with gadolinium is useful in the diagnosis of this condition, preoperative correct diagnosis is usually difficult and the definitive diagnosis must be made during surgery. We describe here a 50-year-old female patient who presented with pain in the lower back for 6 months and a sudden exacerbation of the pain that spread to the left leg as well as numbness in both legs for 2 weeks. MRI demonstrated an intradural mass at the level of L5. Laminectomy was performed, and subsequently durotomy was also performed. An intradural disc fragment was found and completely removed. The patient recovered fully in 3 months. Intradural lumbar disc herniation must be considered in the differential diagnosis of mass lesions in the spinal canal.
Several
plant compounds have been found to possess neuroactive
properties. The aim of this study was to investigate the anticonvulsant
effect of eupafolin, a major active component extracted from Salvia plebeia, a herb used in traditional medicine
for its anti-inflammatory properties. To this end, we assessed the
anticonvulsant effects of eupafolin in rats intraperitoneally (i.p.)
injected with kainic acid (KA) to elucidate this mechanism. Treatment
with eupafolin (i.p.) for 30 min before KA administration significantly
reduced behavioral and electrographic seizures induced by KA, similar
to carbamazepine (i.p.), a widely used antiepileptic drug. Eupafolin
treatment also significantly decreased KA seizure-induced neuronal
cell death and glutamate elevation in the hippocampus. In addition,
eupafolin notably reversed KA seizure-induced alterations in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor subunit GluR2, glutamate decarboxylase 67 (GAD67, GABAergic
enzyme), and Wnt signaling-related proteins, including porcupine,
Wnt1, phosphorylated-glycogen synthase kinase-3β, β-catenin,
and Bcl-2 in the hippocampus. Furthermore, the increased level of
Dickkopf-related protein 1 (Dkk-1, a Wnt signaling antagonist) and
the decreased level of Disheveled1 (Dvl-1, a Wnt signaling activator)
in the hippocampus of KA-treated rats were reversed by eupafolin.
This study provides evidence of the anticonvulsant and neuroprotective
properties of eupafolin and of the involvement of regulation of glutamate
overexcitation and Wnt signaling in the mechanisms of these properties.
These findings support the benefits of eupafolin in treating epilepsy.
Intracranial arachnoid cysts are believed to be congenital; they can become symptomatic in pediatric patients. Chronic subdural hematomas tend to occur in elderly patients with a history of mild head injury a few months prior to the onset of symptoms. However, these two distinct clinical entities sporadically occur together in relatively young patients. We report a 29-year-old man who presented with headache and dizziness of 2 months' duration. Brain computed tomography revealed a huge chronic subdural hematoma over the left frontoparietal lobe, with an incidental finding of an arachnoid cyst over the left sylvian fissure. In light of a literature review, we discuss arachnoid cysts as a possible risk factor for subdural hematoma, especially in young adults.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.